Study details
Enrolling now
Guselkumab vs Golimumab in Psoriatic Arthritis Patients Who Didn't Respond Well to Other Medications
University of Pennsylvania
NCT IDNCT05669833ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
63
Study length
about 3.3 years
Ages
18–80
Locations
14 sites in FL, GA, MA +7
What this study is about
This trial is testing whether switching from a TNF inhibitor (TNFi) to guselkumab, a selective IL23 inhibitor, is more effective than switching to golimumab, another TNFi, for people with psoriatic arthritis who haven't responded well to their current medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Golimumab
- 2.Take Guselkumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
golimumab, guselkumab
Drug routes
injection, intravenous
Endpoints
Secondary: Change in Promis Fatigue
Body systems
Dermatology